CliffBio
biologic

Vaxneuvance

Pneumococcal 15-valent Conjugate Vaccine

Loss of exclusivityJuly 2033FDA regulatory exclusivity expiry
CompanyMerck Sharp & Dohme LLC

Drug detail

Brand nameVaxneuvance
Active ingredientPneumococcal 15-valent Conjugate Vaccine
Strength2.0UG
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalJuly 2021
Marketing statusRx

More from Merck Sharp & Dohme LLC

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Vaxneuvance patent cliff — loss of exclusivity July 2033 | CliffBio